APA (7th ed.) Citation

Wischik, C. M., Stefanacci, R., Bentham, P., Gauthier, S., Zetterberg, H., Wilcock, G. K., . . . Schelter, B. O. (2026). Clinical, imaging and blood biomarker outcomes in a phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer’s disease. The journal of prevention of Alzheimer's disease, 13(3), . https://doi.org/10.1016/j.tjpad.2026.100480

Chicago Style (17th ed.) Citation

Wischik, Claude M., et al. "Clinical, Imaging and Blood Biomarker Outcomes in a Phase 3 Clinical Trial of Tau Aggregation Inhibitor Hydromethylthionine Mesylate in Mild Cognitive Impairment and Mild to Moderate Dementia Due to Alzheimer’s Disease." The Journal of Prevention of Alzheimer's Disease 13, no. 3 (2026). https://doi.org/10.1016/j.tjpad.2026.100480.

MLA (9th ed.) Citation

Wischik, Claude M., et al. "Clinical, Imaging and Blood Biomarker Outcomes in a Phase 3 Clinical Trial of Tau Aggregation Inhibitor Hydromethylthionine Mesylate in Mild Cognitive Impairment and Mild to Moderate Dementia Due to Alzheimer’s Disease." The Journal of Prevention of Alzheimer's Disease, vol. 13, no. 3, 2026, https://doi.org/10.1016/j.tjpad.2026.100480.